title: The risk associated with hyperoncotic colloids in patients with shock.
abstract: OBJECTIVE
  Crystalloids, artificial and natural colloids have been opposed as representing different strategies for shock resuscitation, but it may be relevant to distinguish fluids based on their oncotic characteristics. This study assessed the risk of renal adverse events in patients with shock resuscitated using hypo-oncotic colloids, artificial hyperoncotic colloids, hyperoncotic albumin or crystalloids, according to physician's choice.
  
  
  METHODS
  International prospective cohort study including 1,013 ICU patients needing fluid resuscitation for shock. Patients suffering from cirrhosis or receiving plasma were excluded.
  
  
  RESULTS
  Influence of different types of colloids and crystalloids on the occurrence of renal events (twofold increase in creatinine or need for dialysis) and mortality was assessed using multivariate analyses and propensity score. Statistical adjustment was based on severity at the time of resuscitation, risks factor for renal failure, and on variables influencing physicians' preferences regarding fluids. A renal event occurred in 17% of patients. After adjustment on potential confounding factors and on propensity score for the use of hyperoncotic colloids, the use of artificial hyperoncotic colloids [OR: 2.48 (1.24-4.97)] and hyperoncotic albumin [OR: 5.99 (2.75-13.08)] was significantly associated with occurrence of renal event. Overall ICU mortality was 27.1%. The use of hyperoncotic albumin was associated with an increased risk of ICU death [OR: 2.79 (1.42-5.47)].
  
  
  CONCLUSIONS
  This study suggests that harmful effects on renal function and outcome of hyperoncotic colloids may exist. Although an improper usage of these compounds and confounding factors cannot be ruled out, their use should be regarded with caution, especially because suitable alternatives exist.
authors.affiliation: Réanimation Médicale, AP-HP, Groupe Hospitalier Albert Chenevier, Henri Mondor, 94000 Créteil, France. frederique.schortgen@hmn.aphp.fr
authors.forename: Frédérique
authors.initials: F
authors.lastname: Schortgen
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Girou
authors.forename: Nicolas
authors.initials: N
authors.lastname: Deye
authors.forename: Laurent
authors.initials: L
authors.lastname: Brochard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000418:Albumins / Q000009:adverse effects; D003102:Colloids / Q000009:adverse effects*; D000077324:Crystalloid Solutions; D005060:Europe / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007362:Intensive Care Units; D007552:Isotonic Solutions / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced* / Q000401:mortality; D008875:Middle Aged; D016017:Odds Ratio; D011446:Prospective Studies; D015532:Rehydration Solutions / Q000009:adverse effects*; D012306:Risk; D012769:Shock / Q000628:therapy*
chemical_list: D000418:Albumins; D003102:Colloids; D000077324:Crystalloid Solutions; D007552:Isotonic Solutions; D015532:Rehydration Solutions